Search
Nadide
go.drugbank.com/drugs/DB14128InvestigationalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
VX-702
go.drugbank.com/drugs/DB05470InvestigationalIt acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Celivarone
go.drugbank.com/drugs/DB16012InvestigationalCelivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as
RO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in
FB-825
go.drugbank.com/drugs/DB17598InvestigationalIt is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]
UDP-alpha-D-glucuronic acid
go.drugbank.com/drugs/DB03041ExperimentalA nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis.
Farletuzumab ecteribulin
go.drugbank.com/drugs/DB18857InvestigationalFarletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin),
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 was rationally designed to "let you sleep" rather than depress the entire brain to "make you sleep."
Romifidine
go.drugbank.com/drugs/DB11543ExperimentalVet approvedRomifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species.
TS-104
go.drugbank.com/drugs/DB33943ExperimentalTS-104 is under investigation in clinical trial NCT07814248 (A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy